ATNM Actinium Pharmaceuticals Inc

$ATNM The real catalyst in the data room right now is Actimab-A in Phase 2-3 trials being done by the National Cancer Institute on AML. Under CRADA, the frontline Phase 2-3 triple Trial data for Actimab-A+ Venetoclax+ASTA-727 data is being clean up by Dr. David, and view in the data room by Big Pharma. Don't get me wrong, ATNM-400 is for real, but Actimab-A is the safety net. In past a trial using chemotherapy and Actimab-A on AML patient, over 55 with no other treatment options having a complete remission in the 70% range. If the numbers are good for the triple-Phase 3 trial, being administered by the NCI, an FDA application is sooner rather than later. The second selling point or catalyst is the supply chain in patents and logistics of AC-225. If you are the owner of Venetoclax or ASTA-272 and you are seeing good data, do you act now, or wait and be at the mercy of the players seeking to control ACC-225? Iomb-B down the road will be the cherry on top, who also had outstanding numbers

$ATNM $ATNM $MRK — One to watch Monday, October 26: Merck’s Oncology Investor Event at ESMO, 2:30 PM ET. Merck will outline its oncology strategy and pipeline priorities. Of particular interest to ATNM investors will be any discussion of radiopharmaceuticals, Actinium-225, HER3-targeted therapies, licensing or acquisitions. Actinium has just presented encouraging first-in-human ATNM-400 results, demonstrating HER3-targeted tumour uptake, no dose-limiting toxicities in its initial three-patient cohort, and progression to the second dose level. Merck already has an interest in HER3-directed oncology through its collaboration with Daiichi Sankyo. No confirmed connection between Merck and Actinium, but the timing makes Monday’s presentation worth watching closely.

$ATNM Does anyone really believe that ATNM would be broadcasting a PR about their oral presentation on ATNM-400 if it was bad news? I certainly don’t!

$ATNM The Chemo study mentioned in the last post was a Phase 2-3 study involving CLANG-M + Actimab-A. This study produced an 83% overall no-response rate and a 75% MRD negativity rate, indicating complete eradication of all cancer cells.

$ATNM I have been a shareholder for over five years, and I have lost a lot of money. I'm the first to agree that the company has made a lot of mistakes in communicating with shareholders. However, I do believe in the science and the good it will do for cancer patients. Recent hires at the company reflect a new level of talent, and I'm hopeful they will be allowed to perform and execute so that shareholder value will increase based on the good it will do for patients. Good luck to all longs!

$ATNM Tomorrow should be an interesting day. We are in overbought conditions, hitting a $1.66 high today. Friday closes are always a significant close going into a weekend. This weekend, the ESMO should be releasing a lot of data. Lets see if there is continue to build, or fade action. Today's up volume was far better than yesterday's down volume. A lot of stop-and-start volume with timely gaps in today's trading. Institutions may be accumulating.😄

$ATNM BIG ATNM-400 development. New EANM’26 abstracts confirm ATNM-400 has entered first-in-human clinical development. The Phase 1 mCRPC study says dose escalation is ongoing, with interim human safety, PK, biodistribution and dosimetry data to be presented at EANM. RADIANZ is also enrolling across 5 solid tumors: prostate, NSCLC, breast, colorectal & ovarian. October deck still guides to initial human biodistribution/safety data + target disclosure in Q4. EANM: Oct 17–21. Target remains undisclosed. Human data are coming.

$ATNM I’m all in so far from objective . I’m befuddled why no new large investors have come aboard. If the trials confirm what ATNM says is the science the market is immense. I will not put a value on it because it would sound stupid given the stock is trading at a $1. I hope if c the results are good we can do a better job of selling the story.Hoping for a big Christmas season

$ATNM ⭐ Every pharma company presenting HER3 upregulation, HER3 escape, or HER3 resistance data is unintentionally mapping out the exact tumors Actinium’s HER3‑alpha therapy will target — and dominate — in the future. Let me break this down cleanly, using your preferred analytical style. ⭐ 1. Why HER3 upregulation data from other companies benefits ATNM HER3 upregulation = HER3 turns on when tumors become resistant. This is being shown by: Daiichi (HER3‑DXd) Merck (HER3 escape in EGFR/KRAS/PD‑1 failures) AstraZeneca (HER3 signaling in EGFR‑mutant NSCLC) Roche/Genentech (HER3 activation in HER2‑resistant breast cancer) Novartis (HER3 escape in HER2/ADC resistance pathways) Pfizer (HER3 expression in metastatic breast cancer) Every one of these companies is showing: ✔ HER3 is a universal escape node ✔ HER3 is upregulated in resistance ✔ HER3 is a pan‑tumor target ✔ HER3 is a CNS‑active target ✔ HER3 is a metastatic driver ✔ HER3 is a salvage pathway

$ATNM a whopping $42 million of market cap here…if there is any inkling that this is REAL the first stop should be $200 million or about $6 a share…then up from there as it is proved….

$ATNM buy and HOLD!!!A STRONG BUY FROM MANY ANALYSTS!!!!!GOING UP IN THE NEXT 2 weeks for sure……….PATIENCE!!!!!!!!

$ATNM Had a big Kool Aid breakfast—1679 shares @ 1.59 in premarket. Excited to have gotten it at this price with big Merck presentation on Monday..Looking for a very heavy volume day especially into the close.

$ATNM lomab-act is essentially a lower dose version of lomab-B. If the NIH study going on with lomab-act is successful it would seem reasoble that they wound fund a followup lomab-B study. It would also seem reasonable that the FDA would reexamine their position on lomab-B.

$ATNM the hiring and announcements do not seem like a company preparing to fold - quite the opposite. They know something huge is on the horizon and are pushing forward. This is quite positive.

$ATNM I continue to be dumbfounded that people (including Shorts) would sell their shares for pennies when we literally have the potential of a major catalyst coming in approximately 2 more trading days…it just doesn’t make any sense for anyone to sell!

$ATNM What a week again! Up and coming events will show what is the next new targeted crown champ, Atnm

$ATNM undiscovered with great PR this morning Actinium Pharmaceuticals Unveils ATNM-400 Data at EANM 2026 with a First-In-Human HER3-Targeted Radiotherapy Approach Beyond PSMA in Prostate Cancer By PR Newswire | October 20, 2026, 8:00 AM

$ATNM Well I think that we have shown our … “proof-in-the-pudding”…and we’re off to the next phase. At this stage of our success and unique patented protected progress attacking cancer ANYTHING could happen with BP (partnership or buyout) at ant time! BP SURPRISES may be just around the corner!!! IMHO…It’s time to BUY-n-HOLD your shares!!!!!

$ATNM From this stock value, the only way out is with favorable phase 1 data, that's all that's needed. I expect Selt to present that data in the coming days.

$ATNM THANK YOU JOHNNY FOR ALL YOUR EXPERTISE AND HARD WORK!!!!!!MANY HRS AND DAYS MONTHS WORTH OF INVESTAGATIVE ANALYSIS!!!!!I TRULY APPRECIATE YOU!!!!!!BUYING MORE SHARES IN THE NEAR FUTURE!!!!!!!!!!!!!!!!!!THANK YOU SO MUCH!!!!!!🍀🍀🍀🍀🍀🍀🍀to you always,looking forward to meeting you some day……..